SVRA - Savara Inc.
| Previous Close | 2.4400 |
| Open | 2.4000 |
| Bid | 2.3800 x 900 |
| Ask | 2.4000 x 800 |
| Day's Range | 2.3800 - 2.5600 |
| 52 Week Range | 2.3200 - 13.2490 |
| Volume | 253,768 |
| Avg. Volume | 598,907 |
| Market Cap | 90.531M |
| Beta (3Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3490 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.20 |
- Insider Monkey•15 hours ago
Hedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
- Zacks•6 days ago
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
- Zacks•7 days ago
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
- Business Wire•13 days ago
Savara to Present at the JMP Securities Life Sciences Conference
Savara Inc. , an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m.
- TheStreet.com•13 days ago
Savara Plunges After Lung Disease Drug Fails Phase 3 Trial
were crumbling Thursday, falling more than 75% after the company announced that its lung disease treatment candidate Molgradex failed its Phase 3 study. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer. The company said that was meeting with the Food and Drug Administration and the European Medicines Agency to discuss the results of the study and to determine its next course of action.
- Motley Fool•13 days ago
Here's Why Savara Pharmaceuticals Collapsed Today
Investors just received some bad news about the company's lead drug candidate.
- Zacks•13 days ago
Savara Plunges on Failure of Late-Stage Study on Molgradex
Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.
- TheStreet.com•14 days ago
Savara Shares Slammed on Failed Phase 3 Drug Study
crumpled in after-hours trading Wednesday after the company said a phase 3 trial of its Molgradex drug treatment for a rare lung disease had failed to meet its test goals. "Disappointingly, with the placebo effect stronger than anticipated, the study did not meet its primary endpoint," said Rob Neville, Savara's chief executive officer.
- MarketWatch•14 days ago
Savara stock plummets 75% after drug study fails to hit target
Shares in Savara Inc. , which is seeking to address rare lung diseases, dropped 75% in after-hours trading Wednesday, when the drug company announced that a study failed to hit its target. Savara said a phase 3 study of core pipeline drug Molgradex, which seeks to treat Autoimmune Alveolar Pulmonary Proteinosis, did not meet its primary endpoint. Secondary endpoints were met, and the company said it is figuring out next steps. "We are preparing to meet with the FDA and EMA to discuss the results from this study and to determine our options to seek approval based on the current data, and potentially conduct an additional study incorporating the learnings," Chief Executive Rob Neville said in a statement. Shares were halted ahead of the announcement, after closing at $10.57, which gave the company a market cap of nearly $380 million. When shares were reopened for late trading, the price immediately fell to less than $2.40.
- Business Wire•14 days ago
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
Savara Inc. (SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP. An average A-aDO2 improvement of 12.1 mmHg was observed in the continuous dosing arm, compared to an average A-aDO2 improvement of 8.8 mmHg in the placebo arm. With an estimated 4.6 mmHg treatment difference (p=0.17), the study did not meet its primary endpoint.
- Zacks•16 days ago
Implied Volatility Surging for Savara (SVRA) Stock Options
Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
Motley Fool•last monthSavara Inc. (SVRA) Q1 2019 Earnings Call Transcript
SVRA earnings call for the period ending March 31, 2019.
- Simply Wall St.•last month
Savara Inc. (NASDAQ:SVRA) Is Expected To Breakeven
Savara Inc.'s (NASDAQ:SVRA): Savara Inc. operates as an orphan lung disease company. The US$427m market-cap posted a...
- Zacks•last month
Savara Inc (SVRA) Upgraded to Buy: Here's Why
Savara Inc (SVRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Business Wire•2 months ago
Savara Reports First Quarter 2019 Financial Results and Provides Business Update
Top Line Results from Pivotal Phase 3 IMPALA Study Expected in June 2019
- Business Wire•2 months ago
Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc. (SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Molgradex, the Company’s lead product candidate, is being investigated in a pivotal Phase 3 study, called IMPALA, for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). Topline results from the study are expected in June 2019.
- Business Wire•2 months ago
Savara to Report First Quarter 2019 Financial Results and Provide Business Update
Savara Inc. , an orphan lung disease company, today announced that the Company will report first quarter 2019 financial results and provide a business update on Thursday, May 9, 2019.
- ACCESSWIRE•3 months ago
Savara to Present at the H.C. Wainwright Global Life Sciences Conference in London
AUSTIN, TX / ACCESSWIRE / April 2, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Rob Neville, Chief Executive Officer, will present at the H.C. Wainwright Global ...
- ACCESSWIRE•3 months ago
Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection in People Living with Cystic Fibrosis
AUSTIN, TX / ACCESSWIRE / April 1, 2019 / Savara Inc. (SVRA), an orphan lung disease company, today announced the initiation of ENCORE, a Phase 2a clinical study evaluating its lead product candidate, Molgradex, for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and is also currently in Phase 2a development for NTM in non-CF patients and in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). "People living with CF who have chronic NTM lung infection are in need of improved treatment options to complement current antibiotic regimens," said Rob Neville, Chief Executive Officer.
Motley Fool•3 months agoSavara Inc. (SVRA) Q4 2018 Earnings Conference Call Transcript
SVRA earnings call for the period ending December 31, 2018.
- ACCESSWIRE•3 months ago
Savara Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Business Update
AUSTIN, TX / ACCESSWIRE / March 13, 2018 / Savara Inc. (SVRA), an orphan lung disease company, today reported financial results for the fourth quarter and full year ending December 31, 2018 and provided a business update. ''With the approaching data read-out from our pivotal IMPALA study, we enter 2019 with confidence,'' said Rob Neville, Chief Executive Officer, Savara. ''We've started key commercial preparation activities to support a potential launch as we believe Molgradex could transform the standard-of-care for a debilitating disease with no approved therapies.
- Simply Wall St.•3 months ago
Did Savara Inc. (NASDAQ:SVRA) Insiders Buy Up More Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
- ACCESSWIRE•4 months ago
Savara To Report Q4/Year-End 2018 Financial Results And Business Update On March 13, 2019
AUSTIN, TX / ACCESSWIRE / March 6, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its fourth quarter and year-end 2018 financial results on Wednesday, ...
- ACCESSWIRE•4 months ago
Savara to Present at the 39th Annual Cowen and Company Healthcare Conference
AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today that the company's Chief Executive Officer, Rob Neville, will present at the 39th Annual ...
